| In ZINC since | Heavy atoms | Benign functionality |
|---|---|---|
| January 12th, 2010 | 9 | Yes |
Popular Name: 5-Fluorouracil 5-Fluorouracil
Find On: PubMed — Wikipedia — Google
CAS Numbers: 191047-64-0 , 2794-13-0 , 51-21-8 , 766-63-2 , [51-21-8]
1-fluoro-1h-pyrimidine-2,4-dione
2,4(1H,3H)-Pyrimidinedione, 5-fluoro-
2,4(1H,3H)-Pyrimidinedione, 5-fluoro- (9CI)
2,4-Dihydroxy-5-fluoropyrimidine
4(3H)-Pyrimidinone, 5-fluoro-2-hydroxy- (9CI)
5-Fluor-2,4(1H,3H)-pyrimidindion
5-Fluor-2,4(1H,3H)-pyrimidindion [Czech]
5-Fluor-2,4-dihydroxypyrimidin
5-Fluor-2,4-dihydroxypyrimidin [Czech]
5-Fluor-2,4-pyrimidindiol [Czech]
5-fluoro-1,2,3,4-tetrahydropyrimidine-2,4-dione
5-fluoro-1H-pyrimidine-2,4-dione
5-Fluoro-2,4(1H,3H)-pyrimidinedione
5-fluoropyrimidine-2,4(1H,3H)-dione
5-Fluoropyrimidine-2,4(1H,3H)-dione, 5-Fluoro-2,4-dioxo-1,2,3,4-tetrahydropyrimidine
5-FLUOROURACIL; 5-FU; CPD000038082; SAM002264615
5-FLUOROURACIL; 51-21-8; CPD000038082; SAM002264615
5-FU (TN); 51-21-8; Adrucil (TN); Carac (TN); D00584; Fluoroplex (TN); Fluorouracil (JP16/USP/INN)
5-FU, Carac, Efudex, Fluoroplex
5-FU; 5-Fluorouracil; 51-21-8; C07649; Fluorouracil
Allergan Brand of Fluorouracil
D07974; Fluorouracil (TN); Fluorouracil sodium salt
Dermatech Brand of Fluorouracil
Fluorouracil Monopotassium Salt
Fluorouracil [USAN:INN:BAN:JAN]
fluorouracil; fluorouracilo; fluorouracilum
inhibits thymilidate synthetase
Onkoworks Brand of Fluorouracil
| Type pH range | xlogP | Des A‑Pol Apolar desolvation (kcal/mol) | Des Pol Polar desolvation (kcal/mol) | H Don H-bond donors | H Acc H-bond acceptors | Chg Net charge | tPSA (Ų) | MWT Molecular weight (g/mol) | RB Rotatable bonds | DL |
|---|---|---|---|---|---|---|---|---|---|---|
| Ref Reference (pH 7) | -0.59 | -1.23 | -13.33 | 2 | 4 | 0 | 66 | 130.078 | 0 | ↓ |
| Hi High (pH 8-9.5) | -0.13 | -4 | -48.58 | 1 | 4 | -1 | 69 | 129.07 | 0 | ↓ |
| Mid Mid (pH 6-8) | -0.13 | -3.14 | -32.57 | 1 | 4 | -1 | 69 | 129.07 | 0 | ↓ |
| Note Type | Comments | Provided By |
|---|---|---|
| BP [°C] | 190 - 200 (p=0.1 torr) | Acros Organics |
| Mp [°C] | 278 - 282 | Acros Organics |
| MP | 280 - 282 | Enamine Building Blocks |
| MP | 280-282°(dec) | Matrix Scientific |
| MP | 280-282°(dec.) | Oakwood Chemical |
| MP | 280...282 | Enamine Building Blocks |
| ALOGPS_SOLUBILITY | 5.86e+00 g/l | DrugBank-approved |
| purity | 9.500000000000000e+001 | Enamine Building Blocks Enamine Building Blocks |
| Purity | 98% | Fluorochem |
| Purity | 98+% | Matrix Scientific |
| Purity | 99% | APIChem |
| UniProt Database Links | AIFM2_MOUSE; DPYD_CAEBR; DPYD_CAEEL; DPYD_HUMAN; ENT1_ARATH; ENT3_ARATH; ENT4_ARATH; ENT6_ARATH; ENT8_ARATH; FBX31_HUMAN; MBD4_HUMAN; MBD4_MOUSE; MELK_HUMAN; PREA_ECOLI; ROMO1_HUMAN; S22A7_HUMAN; S22A8_MOUSE; UKL1_ARATH; YCGZ_ECOLI; YJJG_ECO57; YJJG_ECOLI | ChEBI |
| Notes | Antineoplastic agent. Not USP. Not for drug use. | Apollo Scientific |
| Therapy | antineoplastic, pyrimidine antimetabolite | SMDC Iconix |
| Indications | bowl, breast, skin, stomach and oesophagus cancer | KeyOrganics Bioactives |
| Melting_Point | ca 282? dec. | Alfa-Aesar |
| Melting_Point | ca 282° dec. | Alfa-Aesar |
| Target | DNA/RNA Synthesis | Selleck Chemicals |
| PUBCHEM_PATENT_ID | EP0238545A1; EP0238545B1; EP0263213A1; EP0263213B1; EP0754046A1; US5099019; US5175281; US5268477; US5322943; US5380839; US5380840; US5380841; US5382661; US5506354; US5869468; US5891881; US6060463; USRE35053; WO1987001706A2; WO1987007895A1; WO1995026734A1 | IBM Patent Data |
| Patent Database Links | EP0774258; EP1080726; EP1110552; EP1331005; EP1493445; EP1498127; EP1535623; EP1537858; EP1538164; EP1541142; EP1552841; EP1563849; EP1568379; EP1579863; EP1579874; EP1580188; EP1584682; EP1584686; EP1595543; EP1598081; EP1607087; EP1611879; EP1621077; EP | ChEBI |
| H phrase | H341: Suspected of causing genetic defects | Acros Organics |
| H phrase | H341: Suspected of causing genetic defects; H361d: Suspected of damaging the unborn child; H302: Harmful if swallowed; H312: Harmful in contact with skin; H332: Harmful if inhaled; H319: Causes serious eye irritation; H315: Causes skin irritation; H335: M | Acros Organics |
| Warnings | IRRITANT, TOXIC, CORROSIVE | Matrix Scientific |
| PUBCHEM_SUBSTANCE_COMMENT | NCC_SAMPLE_SUPPLIER : LightBiologicals; NCC_SUPPLIER_STRUCTURE_ID : F-599 | NIH Clinical Collection via PubChem |
| P phrase | P301 + P310: IF SWALLOWED: Immediately call a POISON CENTER or doctor/physician | Acros Organics |
| P phrase | P301 + P310: IF SWALLOWED: Immediately call a POISON CENTER or doctor/physician; P260: Do not breathe dust/fume/gas/mist/vapors/spray; P304 + P340: IF INHALED: Remove victim to fresh air and keep at rest in a position comfortable for breathing; P302+ P352 | Acros Organics |
| R phrase | R36/37/38: Irritating to eyes, respiratory system and skin. | Acros Organics |
| R phrase | R36/37/38: Irritating to eyes, respiratory system and skin.; R20/21/22: Harmful by inhalation, in contact with skin and if swallowed.; R63: Possible risk of harm to the unborn child.; R68: Possible risks of irreversible effects. | Acros Organics |
| S phrase | S26: In case of contact with eyes, rinse immediately with plenty of water and seek medical advice. | Acros Organics |
| S phrase | S26: In case of contact with eyes, rinse immediately with plenty of water and seek medical advice.; S36/37/39: Wear suitable protective clothing, gloves and eye/face protection. | Acros Organics |
| PUBCHEM_SUBSTANCE_COMMENT | SAMPLE_SUPPLIER: LightBiologicals; SUPPLIER_STRUCTURE_ID: F-599 | NIH Clinical Collection via PubChem |
| Notes | This pyrimidine analogue, is an antineoplastic agent | Apollo Scientific Bioactives |
| Warnings | Toxic/Corrosive/Irritant | Matrix Scientific |
| Hazard | XN: Harmful | Acros Organics |
| Code | Description | Organism Class | Affinity (nM) | LE (kcal/mol/atom) | Type |
|---|---|---|---|---|---|
| TYSY-3-E | Thymidylate Synthase (cluster #3 Of 3), Eukaryotic | Eukaryotes | 7000 | 0.80 | Binding ≤ 10μM |
| Z103205-4-O | A431 (cluster #4 Of 4), Other | Other | 18 | 1.20 | Functional ≤ 10μM |
| Z103419-1-O | UACC-812 (cluster #1 Of 2), Other | Other | 3100 | 0.86 | Functional ≤ 10μM |
| Z50425-14-O | Plasmodium Falciparum (cluster #14 Of 22), Other | Other | 7943 | 0.79 | Functional ≤ 10μM |
| Z80035-6-O | B16 (Melanoma Cells) (cluster #6 Of 7), Other | Other | 8730 | 0.79 | Functional ≤ 10μM |
| Z80054-2-O | Caco-2 (Colon Adenocarcinoma Cells) (cluster #2 Of 4), Other | Other | 1500 | 0.91 | Functional ≤ 10μM |
| Z80064-6-O | CCRF-CEM (T-cell Leukemia) (cluster #6 Of 9), Other | Other | 5000 | 0.82 | Functional ≤ 10μM |
| Z80088-4-O | CHO (Ovarian Cells) (cluster #4 Of 4), Other | Other | 5000 | 0.82 | Functional ≤ 10μM |
| Z80101-1-O | COLO 320DM (Colon Adenocarcinoma Cells) (cluster #1 Of 2), Other | Other | 1100 | 0.93 | Functional ≤ 10μM |
| Z80120-3-O | DLD-1 (Colon Adenocarcinoma Cells) (cluster #3 Of 5), Other | Other | 6000 | 0.81 | Functional ≤ 10μM |
| Z80125-6-O | DU-145 (Prostate Carcinoma) (cluster #6 Of 9), Other | Other | 4800 | 0.83 | Functional ≤ 10μM |
| Z80136-3-O | FM3A (Breast Carcinoma Cells) (cluster #3 Of 6), Other | Other | 180 | 1.05 | Functional ≤ 10μM |
| Z80156-6-O | HL-60 (Promyeloblast Leukemia Cells) (cluster #6 Of 12), Other | Other | 9500 | 0.78 | Functional ≤ 10μM |
| Z80164-4-O | HT-1080 (Fibrosarcoma Cells) (cluster #4 Of 6), Other | Other | 9450 | 0.78 | Functional ≤ 10μM |
| Z80166-8-O | HT-29 (Colon Adenocarcinoma Cells) (cluster #8 Of 12), Other | Other | 7300 | 0.80 | Functional ≤ 10μM |
| Z80186-7-O | K562 (Erythroleukemia Cells) (cluster #7 Of 11), Other | Other | 2400 | 0.87 | Functional ≤ 10μM |
| Z80192-2-O | KM12 (Colon Adenocarcinoma Cells) (cluster #2 Of 4), Other | Other | 8320 | 0.79 | Functional ≤ 10μM |
| Z80193-8-O | L1210 (Lymphocytic Leukemia Cells) (cluster #8 Of 12), Other | Other | 970 | 0.94 | Functional ≤ 10μM |
| Z80224-5-O | MCF7 (Breast Carcinoma Cells) (cluster #5 Of 14), Other | Other | 9600 | 0.78 | Functional ≤ 10μM |
| Z80268-1-O | MKN-28 (Gastric Epithelial Carcinoma Cells) (cluster #1 Of 2), Other | Other | 2500 | 0.87 | Functional ≤ 10μM |
| Z80269-3-O | MKN-45 (Gastric Adenocarcinoma Cells) (cluster #3 Of 3), Other | Other | 3000 | 0.86 | Functional ≤ 10μM |
| Z80347-2-O | NUGC-3 (Gastric Carcinoma Cells) (cluster #2 Of 2), Other | Other | 4400 | 0.83 | Functional ≤ 10μM |
| Z80362-5-O | P388 (Lymphoma Cells) (cluster #5 Of 8), Other | Other | 609 | 0.97 | Functional ≤ 10μM |
| Z80390-6-O | PC-3 (Prostate Carcinoma Cells) (cluster #6 Of 10), Other | Other | 16 | 1.21 | Functional ≤ 10μM |
| Z80485-4-O | SK-MEL-28 (Melanoma Cells) (cluster #4 Of 6), Other | Other | 4500 | 0.83 | Functional ≤ 10μM |
| Z80490-4-O | SK-MES-1 (cluster #4 Of 4), Other | Other | 310 | 1.01 | Functional ≤ 10μM |
| Z80525-2-O | SW48 (cluster #2 Of 2), Other | Other | 5700 | 0.82 | Functional ≤ 10μM |
| Z80526-3-O | SW480 (Colon Adenocarcinoma Cells) (cluster #3 Of 6), Other | Other | 8100 | 0.79 | Functional ≤ 10μM |
| Z80532-5-O | T-24 (Bladder Carcinoma Cells) (cluster #5 Of 6), Other | Other | 4100 | 0.84 | Functional ≤ 10μM |
| Z80583-6-O | Vero (Kidney Cells) (cluster #6 Of 7), Other | Other | 6810 | 0.80 | Functional ≤ 10μM |
| Z80641-1-O | 791T Cell Line (cluster #1 Of 1), Other | Other | 5500 | 0.82 | Functional ≤ 10μM |
| Z80653-2-O | 9L (Glioma Cells) (cluster #2 Of 2), Other | Other | 1000 | 0.93 | Functional ≤ 10μM |
| Z80682-9-O | A549 (Lung Carcinoma Cells) (cluster #9 Of 11), Other | Other | 9200 | 0.78 | Functional ≤ 10μM |
| Z80686-1-O | AZ-521 Cell Line (cluster #1 Of 1), Other | Other | 3900 | 0.84 | Functional ≤ 10μM |
| Z80712-5-O | T47D (Breast Carcinoma Cells) (cluster #5 Of 7), Other | Other | 600 | 0.97 | Functional ≤ 10μM |
| Z80724-1-O | C170 Cell Line (cluster #1 Of 1), Other | Other | 2000 | 0.89 | Functional ≤ 10μM |
| Z80742-2-O | C6 (Glioma Cells) (cluster #2 Of 3), Other | Other | 6100 | 0.81 | Functional ≤ 10μM |
| Z80874-5-O | CEM (T-cell Leukemia) (cluster #5 Of 7), Other | Other | 9230 | 0.78 | Functional ≤ 10μM |
| Z80928-7-O | HCT-116 (Colon Carcinoma Cells) (cluster #7 Of 9), Other | Other | 8510 | 0.79 | Functional ≤ 10μM |
| Z81020-1-O | HepG2 (Hepatoblastoma Cells) (cluster #1 Of 8), Other | Other | 9200 | 0.78 | Functional ≤ 10μM |
| Z81024-6-O | NCI-H460 (Non-small Cell Lung Carcinoma) (cluster #6 Of 8), Other | Other | 8500 | 0.79 | Functional ≤ 10μM |
| Z81034-5-O | A2780 (Ovarian Carcinoma Cells) (cluster #5 Of 10), Other | Other | 7210 | 0.80 | Functional ≤ 10μM |
| Z81041-1-O | Prostatic Carcinoma Cells (cluster #1 Of 2), Other | Other | 6400 | 0.81 | Functional ≤ 10μM |
| Z81043-2-O | N592 (cluster #2 Of 2), Other | Other | 5400 | 0.82 | Functional ≤ 10μM |
| Z81048-1-O | TSU (Prostatic Carcinoma Cells) (cluster #1 Of 2), Other | Other | 3600 | 0.85 | Functional ≤ 10μM |
| Z81115-6-O | KB (Squamous Cell Carcinoma) (cluster #6 Of 6), Other | Other | 4460 | 0.83 | Functional ≤ 10μM |
| Z81121-1-O | KKLS Cell Line (cluster #1 Of 1), Other | Other | 6200 | 0.81 | Functional ≤ 10μM |
| Z81170-4-O | LNCaP (Prostate Carcinoma) (cluster #4 Of 5), Other | Other | 4900 | 0.83 | Functional ≤ 10μM |
| Z81247-7-O | HeLa (Cervical Adenocarcinoma Cells) (cluster #7 Of 9), Other | Other | 9700 | 0.78 | Functional ≤ 10μM |
| Z81252-9-O | MDA-MB-231 (Breast Adenocarcinoma Cells) (cluster #9 Of 11), Other | Other | 9600 | 0.78 | Functional ≤ 10μM |
| Z81330-1-O | SNU- (cluster #1 Of 1), Other | Other | 2700 | 0.87 | Functional ≤ 10μM |
| Z81331-3-O | SW-620 (Colon Adenocarcinoma Cells) (cluster #3 Of 6), Other | Other | 9000 | 0.78 | Functional ≤ 10μM |
| Z81335-3-O | HCT-15 (Colon Adenocarcinoma Cells) (cluster #3 Of 5), Other | Other | 9710 | 0.78 | Functional ≤ 10μM |
| Z80156-3-O | HL-60 (Promyeloblast Leukemia Cells) (cluster #3 Of 4), Other | Other | 160 | 1.06 | ADME/T ≤ 10μM |
| Z80192-2-O | KM12 (Colon Adenocarcinoma Cells) (cluster #2 Of 2), Other | Other | 7940 | 0.79 | ADME/T ≤ 10μM |
| Z80193-4-O | L1210 (Lymphocytic Leukemia Cells) (cluster #4 Of 4), Other | Other | 560 | 0.97 | ADME/T ≤ 10μM |
| Z80583-3-O | Vero (Kidney Cells) (cluster #3 Of 3), Other | Other | 200 | 1.04 | ADME/T ≤ 10μM |
| Z80901-2-O | HaCaT (Keratinocytes) (cluster #2 Of 2), Other | Other | 400 | 1.00 | ADME/T ≤ 10μM |
| Z80928-2-O | HCT-116 (Colon Carcinoma Cells) (cluster #2 Of 2), Other | Other | 2040 | 0.89 | ADME/T ≤ 10μM |
| Z81247-2-O | HeLa (Cervical Adenocarcinoma Cells) (cluster #2 Of 3), Other | Other | 570 | 0.97 | ADME/T ≤ 10μM |
| Z81335-2-O | HCT-15 (Colon Adenocarcinoma Cells) (cluster #2 Of 2), Other | Other | 6610 | 0.81 | ADME/T ≤ 10μM |
| Uniprot | Swissprot | Description | Affinity (nM) | LE (kcal/mol/atom) | Type |
|---|---|---|---|---|---|
| TYSY_MOUSE | P07607 | Thymidylate Synthase, Mouse | 20 | 1.20 | Binding ≤ 1μM |
| TYSY_MOUSE | P07607 | Thymidylate Synthase, Mouse | 20 | 1.20 | Binding ≤ 10μM |
| Z80641 | Z80641 | 791T Cell Line | 5500 | 0.82 | Functional ≤ 10μM |
| Z80653 | Z80653 | 9L (Glioma Cells) | 1000 | 0.93 | Functional ≤ 10μM |
| Z81034 | Z81034 | A2780 (Ovarian Carcinoma Cells) | 5000 | 0.82 | Functional ≤ 10μM |
| Z103205 | Z103205 | A431 | 18 | 1.20 | Functional ≤ 10μM |
| Z80682 | Z80682 | A549 (Lung Carcinoma Cells) | 1400 | 0.91 | Functional ≤ 10μM |
| Z80686 | Z80686 | AZ-521 Cell Line | 3900 | 0.84 | Functional ≤ 10μM |
| Z80035 | Z80035 | B16 (Melanoma Cells) | 8730 | 0.79 | Functional ≤ 10μM |
| Z80724 | Z80724 | C170 Cell Line | 2000 | 0.89 | Functional ≤ 10μM |
| Z80742 | Z80742 | C6 (Glioma Cells) | 6100 | 0.81 | Functional ≤ 10μM |
| Z80054 | Z80054 | Caco-2 (Colon Adenocarcinoma Cells) | 1500 | 0.91 | Functional ≤ 10μM |
| Z80064 | Z80064 | CCRF-CEM (T-cell Leukemia) | 2000 | 0.89 | Functional ≤ 10μM |
| Z80874 | Z80874 | CEM (T-cell Leukemia) | 8000 | 0.79 | Functional ≤ 10μM |
| Z80088 | Z80088 | CHO (Ovarian Cells) | 5000 | 0.82 | Functional ≤ 10μM |
| Z80101 | Z80101 | COLO 320DM (Colon Adenocarcinoma Cells) | 1100 | 0.93 | Functional ≤ 10μM |
| Z80120 | Z80120 | DLD-1 (Colon Adenocarcinoma Cells) | 6000 | 0.81 | Functional ≤ 10μM |
| Z80125 | Z80125 | DU-145 (Prostate Carcinoma) | 2190 | 0.88 | Functional ≤ 10μM |
| Z80136 | Z80136 | FM3A (Breast Carcinoma Cells) | 180 | 1.05 | Functional ≤ 10μM |
| Z80928 | Z80928 | HCT-116 (Colon Carcinoma Cells) | 1930 | 0.89 | Functional ≤ 10μM |
| Z81335 | Z81335 | HCT-15 (Colon Adenocarcinoma Cells) | 3600 | 0.85 | Functional ≤ 10μM |
| Z81247 | Z81247 | HeLa (Cervical Adenocarcinoma Cells) | 1000 | 0.93 | Functional ≤ 10μM |
| Z81020 | Z81020 | HepG2 (Hepatoblastoma Cells) | 2780 | 0.86 | Functional ≤ 10μM |
| Z80156 | Z80156 | HL-60 (Promyeloblast Leukemia Cells) | 0.1 | 1.56 | Functional ≤ 10μM |
| Z80164 | Z80164 | HT-1080 (Fibrosarcoma Cells) | 1380 | 0.91 | Functional ≤ 10μM |
| Z80166 | Z80166 | HT-29 (Colon Adenocarcinoma Cells) | 1080 | 0.93 | Functional ≤ 10μM |
| Z80186 | Z80186 | K562 (Erythroleukemia Cells) | 2400 | 0.87 | Functional ≤ 10μM |
| Z81115 | Z81115 | KB (Squamous Cell Carcinoma) | 0.1 | 1.56 | Functional ≤ 10μM |
| Z81121 | Z81121 | KKLS Cell Line | 6200 | 0.81 | Functional ≤ 10μM |
| Z80192 | Z80192 | KM12 (Colon Adenocarcinoma Cells) | 8320 | 0.79 | Functional ≤ 10μM |
| Z80193 | Z80193 | L1210 (Lymphocytic Leukemia Cells) | 0.1 | 1.56 | Functional ≤ 10μM |
| Z81170 | Z81170 | LNCaP (Prostate Carcinoma) | 4900 | 0.83 | Functional ≤ 10μM |
| Z80224 | Z80224 | MCF7 (Breast Carcinoma Cells) | 1500 | 0.91 | Functional ≤ 10μM |
| Z81252 | Z81252 | MDA-MB-231 (Breast Adenocarcinoma Cells) | 4700 | 0.83 | Functional ≤ 10μM |
| Z80268 | Z80268 | MKN-28 (Gastric Epithelial Carcinoma Cells) | 2500 | 0.87 | Functional ≤ 10μM |
| Z80269 | Z80269 | MKN-45 (Gastric Adenocarcinoma Cells) | 3000 | 0.86 | Functional ≤ 10μM |
| Z81043 | Z81043 | N592 | 5400 | 0.82 | Functional ≤ 10μM |
| Z81024 | Z81024 | NCI-H460 (Non-small Cell Lung Carcinoma) | 8500 | 0.79 | Functional ≤ 10μM |
| Z80347 | Z80347 | NUGC-3 (Gastric Carcinoma Cells) | 4400 | 0.83 | Functional ≤ 10μM |
| Z80362 | Z80362 | P388 (Lymphoma Cells) | 0.1 | 1.56 | Functional ≤ 10μM |
| Z80390 | Z80390 | PC-3 (Prostate Carcinoma Cells) | 16 | 1.21 | Functional ≤ 10μM |
| Z50425 | Z50425 | Plasmodium Falciparum | 10000 | 0.78 | Functional ≤ 10μM |
| Z81041 | Z81041 | Prostatic Carcinoma Cells | 6400 | 0.81 | Functional ≤ 10μM |
| Z80485 | Z80485 | SK-MEL-28 (Melanoma Cells) | 4500 | 0.83 | Functional ≤ 10μM |
| Z80490 | Z80490 | SK-MES-1 | 310 | 1.01 | Functional ≤ 10μM |
| Z81330 | Z81330 | SNU- | 2700 | 0.87 | Functional ≤ 10μM |
| Z81331 | Z81331 | SW-620 (Colon Adenocarcinoma Cells) | 3380 | 0.85 | Functional ≤ 10μM |
| Z80525 | Z80525 | SW48 | 4400 | 0.83 | Functional ≤ 10μM |
| Z80526 | Z80526 | SW480 (Colon Adenocarcinoma Cells) | 2100 | 0.88 | Functional ≤ 10μM |
| Z80532 | Z80532 | T-24 (Bladder Carcinoma Cells) | 4100 | 0.84 | Functional ≤ 10μM |
| Z80712 | Z80712 | T47D (Breast Carcinoma Cells) | 600 | 0.97 | Functional ≤ 10μM |
| Z81048 | Z81048 | TSU (Prostatic Carcinoma Cells) | 3600 | 0.85 | Functional ≤ 10μM |
| Z103419 | Z103419 | UACC-812 | 3100 | 0.86 | Functional ≤ 10μM |
| Z80583 | Z80583 | Vero (Kidney Cells) | 6810 | 0.80 | Functional ≤ 10μM |
| Z80901 | Z80901 | HaCaT (Keratinocytes) | 400 | 1.00 | ADME/T ≤ 10μM |
| Z80928 | Z80928 | HCT-116 (Colon Carcinoma Cells) | 2040 | 0.89 | ADME/T ≤ 10μM |
| Z81335 | Z81335 | HCT-15 (Colon Adenocarcinoma Cells) | 6610 | 0.81 | ADME/T ≤ 10μM |
| Z81247 | Z81247 | HeLa (Cervical Adenocarcinoma Cells) | 570 | 0.97 | ADME/T ≤ 10μM |
| Z80156 | Z80156 | HL-60 (Promyeloblast Leukemia Cells) | 160 | 1.06 | ADME/T ≤ 10μM |
| Z80192 | Z80192 | KM12 (Colon Adenocarcinoma Cells) | 7940 | 0.79 | ADME/T ≤ 10μM |
| Z80193 | Z80193 | L1210 (Lymphocytic Leukemia Cells) | 560 | 0.97 | ADME/T ≤ 10μM |
| Z80583 | Z80583 | Vero (Kidney Cells) | 200 | 1.04 | ADME/T ≤ 10μM |
| Description | Species |
|---|---|
| E2F mediated regulation of DNA replication | |
| G1/S-Specific Transcription | |
| Pyrimidine biosynthesis |
No pre-computed analogs available. Try a structural similarity search.